Project Grant R21AI188719
Award Date
11/14/24
Completion Date
10/31/26
Dollars Obligated
$216K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on elucidating the role of Akkermansia muciniphila in Group B Streptococcal (GBS) vaginal colonization and ascending infection. The $148,568 award will support research to investigate the specific mechanisms by which A. muciniphila promotes GBS interaction with human vaginal epithelial cells, potentially...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $162,000 in funding to the Rector & Visitors of the University of Virginia (UVA) from September 1, 2024 to August 31, 2026. The project aims to characterize a Type VII secretion system (T7SS) in Group B Streptococcus (GBS) and investigate its role in virulence and immune response. Key objectives include...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $242,250 to The Methodist Hospital Research Institute (HMRI) to evaluate the translational potential of two novel strategies, salivabactin and an engineered probiotic, to treat or prevent Group B Streptococcus (GBS) infections in preclinical mouse models. The primary objective is to assess the efficacy of these...
This $3,613,118 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research supports research to elucidate how the bacterial virulence factor hyaluronidase (HYLB) modulates immune responses and contributes to Group B Streptococcus (GBS) disease in newborns. The research utilizes novel ex vivo human organotypic models and in vivo mouse models to investigate HYLB's role in GBS early and late onset...
This $147,486 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) will support research to investigate the impact of type 2 diabetes on the vaginal microbiome and its influence on susceptibility to the bacterial pathogen Group B Streptococcus (GBS). The research aims to define the homeostatic characteristics of the vaginal microenvironment in type 2 diabetes, and characterize how the diabetic vaginal microbiome interacts with GBS and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $483,000.00 to Case Western Reserve University to conduct research on defining the role of single-cell heterogeneity in bacterial vaginosis (BV). The overarching goal is to identify aspects of diversity that impact BV and provide insights into new strategies for prevention, treatment, and diagnosis. The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 to HMH Hospitals Corporation (doing business as Hackensack University Medical Center) to conduct research on how the fungal pathogen Candida albicans adapts to different host environments, such as the oral and systemic infection niches. The research aims to decipher how the fungal acetylome, regulated by the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $569,210 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado Boulder. The grant will fund research to structurally and functionally characterize three key proteins responsible for resistance to cationic antimicrobial peptides (CAMPs) and the antibiotic colistin in gram-negative bacteria. The research aims to close knowledge gaps around the biochemical...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $265,650 over a 2-year period from February 1, 2025 to January 31, 2027 to HMH Hospitals Corporation (dba Hackensack University Medical Center) to conduct research on the evolutionary dynamics of the fungal pathogen Candida glabrata in the gastrointestinal tract. The study aims to elucidate how antifungal drug treatment and immune dysfunction...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $837,644 to Michigan State University from November 2024 through October 2029. The primary objectives are to develop comprehensive libraries of synthetic oligosaccharides with varied amine/acetylation patterns of poly-β-(1-6)-N-acetylglucosamine (PNAG) and evaluate their potential as effective anti-microbial vaccine...